Company Profile

AMAG Pharmaceuticals Inc (AKA: Advanced Magnetics Inc)
Profile last edited on: 12/4/20      CAGE: 5C9A6      UEI: LK7MJ8XFA3W1

Business Identifier: Iron nanoparticle-based therapeutics
Year Founded
1981
First Award
1986
Latest Award
1999
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1100 Winter Street
Waltham, MA 02451
   (617) 498-3300
   contactus@amagpharma.com
   www.amagpharma.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Fairly active in SBIR in its early years and having gone public more or less coincident with the firm's program engagement, AMAG Pharmaceuticals Inc (NASDAQ:AMAG) organized primarily around development of products to treat iron deficiency anemia (IDA) in adult patients. The firm also had a strong presense and portfolio of development-stage assets in women's health and hematology/oncology. In November 2020, the firm was itself acquired by Covis Pharma for a reported amount of $498M and absorbed into the Corvis Pharma Group with senior management remaining in place. Headquartered in Luxembourg with operations in Zug, Switzerland, Covis is specialty pharmaceutical company with a global presense marketing therapeutic for patients with life-threatening conditions and chronic illnesses.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : AMAG
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 1 NIH $98,706
Project Title: Sentinel Lymph Node Staging With Magnetic Nanoparticles
1992 1 NIH $50,000
Project Title: Hepatic Directed Antiviral Agents
1992 1 NIH $49,997
Project Title: Receptor directed superparamagnetic MRI contrast agents
1991 2 NIH $318,634
Project Title: Hepatocyte-Directed Magnetic Resonance Contrastagents
1989 2 NIH $350,000
Project Title: Ferrite particles as NMR imaging contrast agents

Key People / Management

  Bill Heiden -- CEO

  Scott Myers -- President and Chief Executive Officer

  Brian J G Pereira -- President

  Michael N Avallone -- Chief Financial Officer

  Tony Casciano -- Executive Vice President, Chief Operating Officer

  Philip M Enriques

  Jerome Goldstein -- Chairman, Chief Executive Officer and Co-Founder

  Lisa Gordon -- Vice President - Business Development

  Lee Josephson

  Lisa Kiniklis

  Jerome W Lewis

  Kenneth G Paul

  Brian Piekos -- Interim Chief Financial Officer

  Kelly Schick -- Senior Vice President, Chief Human Resources Officer and Head of Corporate Engag

  Joseph D Vittiglio -- Executive Vice President, General Counsel, Chief Business Officer & Corporate Se